Toxoplasma gondii cylclic GMP dependent protein kinase G as a chemotherapeutic target for antiprotozoal agents
View Patent ↗Protozoal cyclic GMP dependent protein kinases have been isolated and cloned. These enzymes may be used in screening assays to identify potential antiprotozoal agents.
1. A substantially pure cGMP dependent protein kinase comprising the amino acid sequence as set forth in SEQ ID NO:13.
2. A method of screening for substances which inhibit the kinase activity of the substantially pure cGMP dependent protein kinase of claim 1 , comprising contacting said substantially pure cGMP dependent protein kinase with a substance to be screened and measuring the cGMP dependent protein kinase activity, wherein inhibition of the cGMP dependent protein kinase activity indicates the substance is an inhibitor of the cGMP dependent protein kinase activity of the substantially pure cGMP dependent protein kinase of claim 1 .
3. A method for identifying an agent effective at inhibiting the kinase activity of the substantially pure cGMP dependent protein kinase of claim 1 , said method comprising the steps of: (i) combining in a reaction mixture (a) a test agent, (b) the substantially pure cGMP dependent protein kinase of claim 1 , (c) a suitable substrate for said kinase of (b) above, and (d) labeled ATP; and (ii) determining the extent to which the test agent inhibits phosphorylation of the substrate as compared to a control reaction lacking the test compound, wherein inhibition of phosphorylation of the substrate in the presence of the compound is indicative that the test agent is an agent effective at inhibiting the kinase activity of the substantially pure cGMP dependent protein kinase of claim 1 .
4. A method of screening for a compound that inhibits the binding or kinase activity of the substantially pure cGMP dependent protein kinase of claim 1 , said method comprising: (a) combining the substantially pure cGMP dependent protein kinase of claim 1 with at least one test compound under conditions permissive for the activity of said kinase; and (b) assessing the binding or kinase activity of said kinase in the presence of the test compound; and (c) comparing the binding or kinase activity of said kinase in the presence of the test compound with the binding or kinase activity of said kinase in the absence of the test compound, wherein a decrease in the binding or kinase activity is indicative of a compound that inhibits the binding or kinase activity of the substantially pure cGMP dependent protein kinase of claim 1 .